358 related articles for article (PubMed ID: 28381172)
1. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147
Lv Y; Wang T; Fan J; Zhang Z; Zhang J; Xu C; Li Y; Zhao G; He C; Meng H; Yang H; Wang Z; Liu J; Chen J; Wang L
Tumour Biol; 2017 Apr; 39(4):1010428317695927. PubMed ID: 28381172
[TBL] [Abstract][Full Text] [Related]
2. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
3. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.
Jiang Z; Hao Y; Ding X; Zhang Z; Liu P; Wei X; Xi J
Tumour Biol; 2016 Aug; 37(8):10383-92. PubMed ID: 26846105
[TBL] [Abstract][Full Text] [Related]
4. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
5. SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.
Zhang L; Guo X; Zhang L; Yang F; Qin L; Zhang D; Qin Y
Mol Carcinog; 2018 Mar; 57(3):440-450. PubMed ID: 29178392
[TBL] [Abstract][Full Text] [Related]
6. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
7. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA
Chen X; Xie R; Gu P; Huang M; Han J; Dong W; Xie W; Wang B; He W; Zhong G; Chen Z; Huang J; Lin T
Clin Cancer Res; 2019 Feb; 25(4):1389-1403. PubMed ID: 30397178
[TBL] [Abstract][Full Text] [Related]
9. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.
Kang MJ; Kim HP; Lee KS; Yoo YD; Kwon YT; Kim KM; Kim TY; Yi EC
Proteomics; 2013 May; 13(10-11):1714-25. PubMed ID: 23554123
[TBL] [Abstract][Full Text] [Related]
11. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
[TBL] [Abstract][Full Text] [Related]
13. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
[TBL] [Abstract][Full Text] [Related]
14. Notum enhances gastric cancer stem-like cell properties through upregulation of Sox2 by PI3K/AKT signaling pathway.
Liu Y; Chen H; Xiao L; Dong P; Ma Y; Zhou Y; Yang J; Bian B; Xie G; Chen L; Shen L
Cell Oncol (Dordr); 2024 Apr; 47(2):463-480. PubMed ID: 37749430
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.
Vazquez-Martin A; Cufí S; López-Bonet E; Corominas-Faja B; Cuyàs E; Vellon L; Iglesias JM; Leis O; Martín AG; Menendez JA
Cell Cycle; 2013 Nov; 12(22):3471-7. PubMed ID: 24107627
[TBL] [Abstract][Full Text] [Related]
16. The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer.
Wang Y; Yang W; Pu Q; Yang Y; Ye S; Ma Q; Ren J; Cao Z; Zhong G; Zhang X; Liu L; Zhu W
J Biomed Sci; 2015 Jul; 22(1):52. PubMed ID: 26156586
[TBL] [Abstract][Full Text] [Related]
17. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
18. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation.
Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL
Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135
[TBL] [Abstract][Full Text] [Related]
19. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription.
Yu JM; Sun W; Wang ZH; Liang X; Hua F; Li K; Lv XX; Zhang XW; Liu YY; Yu JJ; Liu SS; Shang S; Wang F; Yang ZN; Zhao CX; Hou XY; Li PP; Huang B; Cui B; Hu ZW
Nat Commun; 2019 Dec; 10(1):5720. PubMed ID: 31844113
[TBL] [Abstract][Full Text] [Related]
20. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.
Xu C; Xie D; Yu SC; Yang XJ; He LR; Yang J; Ping YF; Wang B; Yang L; Xu SL; Cui W; Wang QL; Fu WJ; Liu Q; Qian C; Cui YH; Rich JN; Kung HF; Zhang X; Bian XW
Cancer Res; 2013 May; 73(10):3181-9. PubMed ID: 23539445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
